Replies to post #36 on Nektar Therapeutics (NKTR)

[SeriousMoney]

Great assessment, B. I think we've got a real winner here, thanks to the baby boomers who are rapidly blooming into diabetic candidates. Hey, I resemble that remark! :)

[SeriousMoney]

Nektar Therapeutics "buy"
Wednesday, May 17, 2006 4:56:33 AM ET
WR Hambrecht & Co

NEW YORK, May 17 (newratings.com) - Analysts at WR Hambrecht maintain their "buy" rating on Nektar Therapeutics (NKTR.NAS). The target price is set to $30.

In a research note published yesterday, the analysts mention that the company's Exubera product has been approved and is to be launched soon. Nektar Therapeutics has implemented cost cutting measures on everything except Exubera, which is expected to boost the company's earnings over the next several years, the analysts say. The recent decline in the company's share price offers an attractive investment opportunity, WR Hambrecht adds.

http://www.newratings.com/analyst_news/article_1277370.html

[SeriousMoney]

Nektar Gets Fast-Track for Lung Drug
The Associated Press
May 22, 2006, 9:38AM

SAN CARLOS, Calif. — Biotech drug maker Nektar Therapeutics said Monday that Food and Drug Administration has given a fast-track designation to its lung infection prevention drug.

A fast-track designation allow a company to submit clinical trial data to the FDA as it becomes available, and get feedback, rather than having to wait and file it all at once.

The designation covers Nektar's Amphotericin B Inhalation Powder to help prevent fungal infections in the lungs in patients who are taking medications that suppress the immune system following organ or stem cell transplants to reduce the chances of rejection.

In February, Nektar received orphan drug status for the treatment. The status is given to drugs that treat diseases affecting less than 200,000 people in the United States. It allows seven years of market exclusivity if the drug is approved along with tax credits and help in designing a clinical trial for approval.

Nektar shares fell 2 cents to $19.68 in morning trading on the Nasdaq.

http://www.chron.com/disp/story.mpl/ap/fn/3879543.html